Építés alatt – nem éles oldal
Belépés
Leállítva4. fázis

Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine

A legfontosabb adatok

Ki végzi
Messoud Ashina, MD
Hol
Dánia1 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Leállítva
Fázis
4. fázis
Résztvevők
8 fő vett részt
Kezdés
2022. jún. 30.
Befejezés
2024. ápr. 15.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Almotriptan 12.5 Mg Oral Tablet
  • Ubrogepant 50Mg Tab
A regiszteradat frissítve
2025. május 31.
Miért állt le
Issues with recruitment

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • Subject has provided informed consent prior to initiation of any study-specific activities/procedures
  • Aged 18 to 65 years upon entry into screening
  • History of migraine (with or without aura) for greater than or equal to 12 months before screening according to the ICHD-3 criteria based on medical records and/or patient self-report
  • Not more than 12 attacks per month with moderate to severe headache pain in each of the previous 3 months

Ki nem vehet részt

  • Has taken medication for acute treatment of headache (including acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), triptans, ergotamine, opioids, or combination analgesics) on 10 or more days per months in the previous 3 months
  • Required hospital treatment of a migraine attack 3 or more times in the previous 6 months; Other Medical Conditions
  • Has a history of any prior gastrointestinal conditions (e.g., diarrhea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of investigational product; participants with prior gastric bariatric interventions which have been reversed are not excluded
  • Current treatment with monoclonal antibodies targeting calcitonin gene related piptide (CGRP) or CGRP receptors, or current use of small-molecule CGRP receptor antagonist (e.g. erenumab, fremanezumab, galcaneszumab or atogeptant)
  • Changes in treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin norepinephrine reuptake inhibitors (SNRI) within the last two months
  • Use of the following medication within 30 days prior to screening:; Strong and moderate cytochrome P450 3A4 (CYP3A4) inhibitors, including but not limited to systemic (oral/IV) itraconazole, ketoconazole, fluconazole; erythromycin, clarithromycin, telithromycin; diltiazem, verapamil; aprepitant; cyclosporine; nefazodone; cimetidine; quinine; and HIV protease inhibitors; Strong and moderate CYP3A4 inducers, including but not limited to barbiturates (eg, phenobarbital and primidone), systemic (oral/IV) glucocorticoids, nevirapine, efavirenz, pioglitazone, carbamazepine, phenytoin, rifampin, rifabutin, and St. John's wort; Inhibitors of the BCRP (breast cancer resistance protein) transporter (eg, rifampicin); Drugs with narrow therapeutic margins (eg, digoxin, warfarin); Other Exclusions
  • Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 16 weeks after the last dose of investigational product
  • Female subjects of childbearing potential unwilling to use 1 acceptable method of effective contraception during treatment and for an additional 16 weeks after the last dose of investigational product
  • Disease Related
  • History of cluster headache or hemiplegic migraine headache
  • Has a history of migraine aura with diplopia or impairment of levels of consciousness, hemiplegic migraine, or retinal migraine
  • Has a chronic non-headache pain condition requiring daily pain medication
  • Has a history of malignancy in the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
  • History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion; Medication related
  • Greater than 50 years of age at migraine onset
  • Inability to differentiate between migraine from other headaches
  • The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior
  • Start of new preventive migraine treatment within the last two months
  • Change in dosage of ongoing preventive migraine treatment within the last two months
  • Female subjects of childbearing potential with a positive pregnancy test assessed at screening or day 1 by a urine pregnancy test
  • Evidence of current pregnancy or breastfeeding per subject self-report or medical records
  • Subject has known sensitivity to any of the products or components to be administered during dosing
  • Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (e.g, Clinical Outcome Assessments) to the best of the subject and investigator's knowledge

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

In a real-world population of adults with migraine, the investigators would like to investigate whether 12.5 mg almotriptan is non-inferior to 50 mg ubrogepant in terms of pain freedom at 2 hours after drug intake.

A vizsgálat 2 csoportja

  • AlmotriptanA vizsgált kezelés

    12.5 mg almotriptan taken orally once

    Kezelés: Almotriptan 12.5 Mg Oral Tablet

  • UbrogepantMár használt kezelés, összehasonlításként

    50 mg ubrogepant taken orally once

    Kezelés: Ubrogepant 50Mg Tab

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (ATOM).
A regiszteradat frissítve
2025. május 31.